ArticleJournal of thoracic disease2018
Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 41 citations in OpenAlex.
- Integrating multimodal data for precise subtyping and prognostication in patients with pulmonary mucinous adenocarcinoma.Translational cancer research · 2026Article
- A 45-Year-Old Woman With a Persistent Cavitary Consolidation.CHEST pulmonary · 2026Article
- Prognostic value of integrated FDG PET/CT avidity and CT morphologic subtypes in invasive mucinous adenocarcinoma of the lung.Annals of nuclear medicine · 2026Article
- Analysis of prognostic factors influencing brain metastasis in EGFR-mutant lung adenocarcinoma and comparison of prognostic assessment models.Oncology letters · 2026Article
- Identification of the lymph node metastasis atlas and optimal lymph node dissection strategy in patients with resectable lung invasive mucinous adenocarcinoma: a real-world multicenter study.Military Medical Research · 2025Article
- Bilateral orthotopic lung transplantation for the patient with lung-limited invasive mucinous adenocarcinoma: a case-based literature review.The oncologist · 2025Review
- Prognostic analysis and development of a predictive model for pulmonary invasive mucinous adenocarcinoma.Journal of thoracic disease · 2025Article
- Demographic and prognostic factors affecting survival in invasive mucinous adenocarcinoma: a national cancer database analysis.Medical oncology (Northwood, London, England) · 2025Article
- Sublobectomy versus lobectomy for peripheral small-sized pulmonary mucinous adenocarcinoma.Journal of thoracic disease · 2025Article
- [Advances on Molecular Mechanism and Clinical Treatment in Invasive Mucinous Adenocarcinoma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Nomogram model for the diagnosis of solitary nodular pulmonary mucinous adenocarcinoma.Scientific reports · 2024Article
- Radiological Features of Primary Pulmonary Invasive Mucinous Adenocarcinoma Based on 312 Consecutive Patients.The clinical respiratory journal · 2024Article
- Nomogram for predicting prognosis and identifying chemotherapy beneficiaries for completely resected stage I invasive mucinous lung adenocarcinoma.Translational lung cancer research · 2024Article
- Efficacy of Touch Imprint Cytology in Intraoperative Diagnosis of Invasive Mucinous Adenocarcinoma of the Lung: A Case Report and Literature Review.Clinics and practice · 2024Article
- Clinicopathologic Features and Survival Outcomes of Primary Lung Mucinous Adenocarcinoma Based on Different Radiologic Subtypes.Annals of surgical oncology · 2024Article
- Surgical resection of a large invasive mucinous adenocarcinoma: A case report.Clinical case reports · 2023Article
- Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study.Medical oncology (Northwood, London, England) · 2023Article
- Comparison of treatment strategies for resectable locally advanced primary mucinous adenocarcinoma of the lung.Cancer medicine · 2023Article
- Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma.BMC pulmonary medicine · 2023Article
- Prognosis of resected invasive mucinous adenocarcinoma compared with the IASLC histologic grading system for invasive nonmucinous adenocarcinoma: Surgical database study in the TKIs era in Korea.Thoracic cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2015, the World Health Organization (WHO) announced a new classification of lung tumors. Mucinous bronchioloalveolar adenocarcinomas were reclassified as invasive mucinous adenocarcinomas (IMAs). Due to the rarity or this tumor type, conflicting clinical outcomes have been reported based on small patient numbers.
methodsPatients diagnosed as primary lung nonmucinous adenocarcinoma (NMA) or IMA from 2000 to 2014 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. General features of each IMA were explored and the effect of histological characteristics on lung cancer-specific survival was analyzed in matched samples using the TNM staging system.
resultsThe incidence of IMA among all primary lung cancer patients was 0.2% (1,783/1,154,742), and the incidence of IMA among patients with a primary resected lung adenocarcinoma was 1.5% (531/35,406). IMAs tended to be located in the lower lobe (P<0.001), be well differentiated (P<0.001), and be N0 (91.7%
conclusionsThe histologic type of the tumor, whether IMA or not, did not affect lung cancer-specific survival times among patients with a primary M0 stage lung adenocarcinoma. When stratified by the TNM staging system, patents that required pneumonectomy, sublobar resection or radiation had shorter lung cancer-specific survival times.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.